Menu Search
Equities

iRhythm Technologies Inc

I25:DUS

iRhythm Technologies Inc

Actions
  • Price (EUR)81.50
  • Today's Change-1.00 / -1.21%
  • Shares traded--
  • 1 Year change+13.19%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 08:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

iRhythm Technologies, Inc. is a digital health care company, which creates solutions that detect, predict, and prevent disease. The Company designs, develops, and commercializes device-based technology to provide ambulatory cardiac monitoring services. It offers three Zio System options: the Zio Monitor System, the Zio XT System, and the Zio AT System. It offers its Zio ambulatory cardiac monitoring services, including long-term continuous monitoring, short-term continuous monitoring, and mobile cardiac telemetry monitoring services (Zio Services), using its Zio Systems. The Zio Monitor System is a prescription-only, remote ECG monitoring system that consists of a patch ECG monitor (the Zio Monitor patch) that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software (ZEUS) System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period.

  • Revenue in USD (TTM)560.03m
  • Net income in USD-150.66m
  • Incorporated2006
  • Employees2.00k
  • Location
    iRhythm Technologies Inc699 8th Street, Suite 600SAN FRANCISCO 94103United StatesUSA
  • Phone+1 (415) 632-5700
  • Fax+1 (302) 655-5049
  • Websitehttps://www.irhythmtech.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.